Shares of Allergan plc (NYSE:AGN) hit a new 52-week low during mid-day trading on Friday . The company traded as low as $158.21 and last traded at $158.74, with a volume of 2626172 shares trading hands. The stock had previously closed at $164.20.

A number of analysts recently issued reports on AGN shares. JPMorgan Chase & Co. set a $275.00 price target on Allergan and gave the company a “buy” rating in a report on Sunday, October 22nd. Cowen set a $280.00 price target on Allergan and gave the company a “buy” rating in a report on Friday, October 20th. Sanford C. Bernstein set a $252.00 price target on Allergan and gave the company a “buy” rating in a report on Wednesday, October 18th. Deutsche Bank set a $251.00 price target on Allergan and gave the company a “buy” rating in a report on Tuesday, October 17th. Finally, UBS Group set a $255.00 price target on Allergan and gave the company a “buy” rating in a report on Tuesday, October 17th. Two research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $227.23.

The firm has a market capitalization of $54,130.00, a P/E ratio of -13.58, a P/E/G ratio of 1.18 and a beta of 1.19. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.04 and a quick ratio of 1.08.

Allergan (NYSE:AGN) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $4.86 EPS for the quarter, topping analysts’ consensus estimates of $4.74 by $0.12. The company had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. Allergan’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $3.90 earnings per share. equities analysts predict that Allergan plc will post 15.56 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Stockholders of record on Wednesday, February 28th will be given a dividend of $0.72 per share. This is an increase from Allergan’s previous quarterly dividend of $0.70. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.77%. Allergan’s dividend payout ratio is presently -23.35%.

In other Allergan news, Director Christopher J. Coughlin purchased 10,000 shares of Allergan stock in a transaction dated Tuesday, December 5th. The shares were acquired at an average cost of $163.30 per share, with a total value of $1,633,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider William Meury sold 11,807 shares of the company’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $173.89, for a total value of $2,053,119.23. The disclosure for this sale can be found here. Over the last ninety days, insiders have bought 17,630 shares of company stock worth $2,890,057. Insiders own 0.36% of the company’s stock.

Hedge funds have recently modified their holdings of the company. Cable Hill Partners LLC increased its position in shares of Allergan by 255.2% during the third quarter. Cable Hill Partners LLC now owns 515 shares of the company’s stock worth $106,000 after purchasing an additional 370 shares in the last quarter. Rockefeller Financial Services Inc. increased its position in shares of Allergan by 283.7% during the third quarter. Rockefeller Financial Services Inc. now owns 541 shares of the company’s stock worth $111,000 after purchasing an additional 400 shares in the last quarter. Phocas Financial Corp. acquired a new position in shares of Allergan during the second quarter worth $150,000. BB&T Investment Services Inc. increased its position in shares of Allergan by 1,308.2% during the third quarter. BB&T Investment Services Inc. now owns 690 shares of the company’s stock worth $139,000 after purchasing an additional 641 shares in the last quarter. Finally, WFG Advisors LP increased its position in shares of Allergan by 20.9% during the second quarter. WFG Advisors LP now owns 793 shares of the company’s stock worth $193,000 after purchasing an additional 137 shares in the last quarter. 80.23% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://theolympiareport.com/2018/02/11/allergan-agn-reaches-new-1-year-low-at-158-21.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.